Using an index-based approach to assess the population-level appropriateness of empirical antibiotic therapy

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 286-293

  Ciccolini, M ^a   Spoorenberg, V ^b   Geerlings, S E ^b   Prins, J M ^b   Grundmann, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antimicrobial resistance; Prescription guidelines; Surveillance

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CEPHALOSPORIN; COTRIMOXAZOLE; GENTAMICIN; NITROFURANTOIN; QUINOLONE DERIVATIVE; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONCEPTUAL FRAMEWORK; DIAGNOSIS RELATED GROUP; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG RESISTANCE INDEX; HUMAN; MAJOR CLINICAL STUDY; PHARMACOLOGICAL PARAMETERS; POPULATION; PRACTICE GUIDELINE; PROGRAM APPROPRIATENESS; URINARY TRACT INFECTION; BACTERIAL INFECTIONS; MICROBIOLOGY; NETHERLANDS; PROCEDURES; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; GUIDELINES AS TOPIC; HUMANS; NETHERLANDS; URINARY TRACT INFECTIONS;

EID: 84928338289     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku336     Document Type: Article

References (15)

1. Leibovici L, Shraga I, Drucker M et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-86.
2. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008; 14 Suppl 3: 15-21.
3. Martinez R, Reyes S, Lorenzo MJ et al. Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med 2009; 30: 172-8.
4. Wilke M, Grube RF, Bodmann KF. Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non-guideline adherent therapy. Eur J Med Res 2011; 16: 315-23.
5. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis 2009; 22: 352-8.
6. Prins JM, Degener JE, de Neeling AJ et al. Experiences with the Dutch Working Party on antibiotic policy (SWAB). Euro Surveill 2008; 13: pii=19037.
7. Allerberger F, Gareis R, Jindrák V et al. Antibiotic stewardship implementation in the EU: theway forward. Expert Rev Anti Infect Ther 2009; 7: 1175-83.
8. Laxminarayan R, Klugman KP. Communicating trends in resistance using a drug resistance index. BMJ Open 2011; 1: e000135.
9. Dutch Foundation of theWorking Party on Antibiotic Policy (SWAB). NethMap 2010-2013: Consumption of Antimicrobial Agents and Antimicrobial Resistance Among Medically Important Bacteria in The Netherlands. http://www.swab.nl.
10. ECDC. Antimicrobial Resistance Surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2012.
11. ECDC. Surveillance of Antimicrobial Consumption in Europe, 2010. Stockholm: ECDC, 2013.
12. Geerlings SE, van den Broek PJ, van Haarst E et al. Optimalization of the Antibiotic Policy in The Netherlands X: SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections. Amsterdam: SWAB, 2006.
13. Geerlings SE, van Nieuwkoop C, van Haarst E et al. SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults. Nijmegen: SWAB, 2013. http://www.swab.nl.
14. Spoorenberg V, Prins JM, Stobberingh EE et al. Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence. Eur J Clin Microbiol Infect Dis 2013; 32: 1445-56.
15. van de Sande N, Thijsen S, Leverstein-van Hall M. Antibioticaresistentiesurveillance in Nederland: ISIS-AR en ISISweb. Ned Tijdschr Med Microbiol 2010; 18: 10-8.